Aug. 17, 2017
WuXi Biologics and its Chinese partner, Harbin Gloria Pharmaceuticals, announced that an exclusive license to the anti-PD-1 antibody GLS-010 has been granted to Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies.
Previously, Gloria has contracted WuXi Biologics to discover and develop its GLS-010, a novel anti-PD-1 antibody. The GLS-010 is currently being evaluated in cancer patients in phase I clinical studies in China.
Arcus has licensed its exclusive development and commercialization rights in North America, Europe, Japan and certain other territories.
Based on the terms of the agreement, Arcus will pay $18.5 million in upfront payments as well as development and regulatory milestones which could total up to $422.5 million for the development and approval of 11 products that include GLS-010 as a component. WuXi Biologics and Gloria, through an existing agreement, will also receive commercial milestones of up to $375 million which could result in aggregate payments from Arcus of $816 million. Arcus will also pay tiered royalties on net sales of GLS-010. In addition, WuXi Biologics and Arcus intend to enter into an exclusive 3-year agreement for the development of Arcus' biologics portfolio.